

Special Issue

Immunotherapy and Targeted Therapy in Gynecologic Cancer: Current Status and Challenges

Message from the Guest Editors

This Special Issue will highlight both the achievements and ongoing challenges in the application of personalized approaches to immunotherapy and targeted treatment in gynecologic oncology. A central focus will be placed on the role of predictive and prognostic biomarkers in guiding therapy selection, monitoring treatment responses, and anticipating resistance. Precision oncology strategies—including multi-omic profiling, individualized risk stratification, and real-world implementation—will be explored to enhance therapeutic outcomes across diverse gynecologic tumors. We welcome submissions of original research articles, systematic reviews, meta-analyses, and translational studies investigating immunotherapy, targeted therapies, biomarker discovery, personalized treatment algorithms, and the development of clinical trials within a precision medicine framework. By gathering multidisciplinary contributions, we hope to provide an updated and comprehensive resource for optimizing patient-tailored care in gynecologic oncology.

Guest Editors

Dr. Brigida Anna Maiorano

Department of Medical Oncology, IRCCS San Raffaele Hospital, 20132 Milan, Italy

Dr. Mauro Francesco Pio Maiorano

1. Unit of Obstetrics and Gynecology, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", Policlinico of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
2. Gynecologic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy

Deadline for manuscript submissions

31 January 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/238433

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).